Conditions: Heart Failure
Keywords: Heart failure with normal ejection fraction Elderly
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 52
Healthy volunteers: no

Brief summary:
The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection fraction (HFNEF).

Detailed description:
Heart Failure with Normal Ejection Fraction (HFNEF) is the most common form of heart failure, particularly in older persons. However, the optimal therapy for this disorder has not been defined. The primary chronic symptom in HFNEF is exercise intolerance, manifested by shortness of breath and fatigue with exercise. This is the major determinant of quality of life, can be measured objectively and reproducibly and is modifiable.

Arms:
arm 1: 50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo. arm 2: 50% of subjects will be randomized to placebo.

Interventions: intervention 1: aliskiren intervention 2: placebo
Intervention descriptions: intervention 1: aliskiren 300mg qd versus placebo for 24 weeks. intervention 2: placebo qd for 24 weeks

Protocol document: